Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury

MT Newswires Live07-24

Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.

The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.

The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.

The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653166706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653166706","market":"us","top_or_hot":-1,"title":"Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury","media":"MT Newswires Live","content":"<html><body><p> Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.</p><p>The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.</p><p>The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.</p><p>The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-24 13:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.</p><p>The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.</p><p>The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.</p><p>The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCI.AU","symbol_name":"Silver City Minerals Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653166706","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653166706","pubTimestamp":1784871689,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kringle Pharma  has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury , according to a Friday filing.The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCI.AU":"Silver City Minerals Ltd","SCI":"Service Corp International","BK4548":"巴美列捷福持仓","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","BK4192":"特殊消费者服务","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC"},"translate_title":"Kringle Pharma 启动 Oremepermin Alfa 治疗急性脊髓损伤的额外三期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCI":1,"SCI.AU":1},"content_text":"Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653166706","isCrawlerRequest":true}